OriCiro Genomics, based in Tokyo, develops and commercializes cell-free synthesis and amplification technology for genome-scale large DNA aimed at gene and cell-based therapies and synthetic biology. Its core tool enables synthesis and amplification of large DNA for use in research, development and manufacturing. The technology is applied across multiple industries including pharmaceuticals, diagnostics, agriculture and food. The company closed a Series B2 financing of undisclosed amount in which Asahi Kasei Medical Co., Ltd. invested. OriCiro intends to use the investment to accelerate growth and leverage expected synergies with Asahi Kasei Medical in the healthcare area. OriCiro Genomics, founded in December 2018 and based in Tokyo, develops cell-free cloning technology for large circular DNA. Its flagship OriCiro Cell-Free Cloning System enables cell-free amplification of large circular DNA, eliminating reliance on E. coli cloning and traditional plasmid DNA supply for pharmaceutical use and drug discovery services. The company targets applications in advanced therapy and synthetic biology. Proceeds from its latest financing will be used to expand manufacturing capabilities, advance R&D, establish a US subsidiary for business growth, accelerate patent filing, and recruit required talent. Since inception the company has raised ¥1.4 billion in total funding.

Total raised

$9M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2021